1. Comparison of Outcomes in Patients With Versus Without Diabetes Mellitus After Revascularization With Everolimus- and Sirolimus-Eluting Stents (from the SORT OUT IV Trial) 
Lisette Okkels Jensen, MD, DMSci, PhD, Per Thayssen, MD, DMSci, Anders Junker, MD, PhD, Michael Maeng, MD, PhD, Hans-Henrik Tilsted, MD, Anne Kaltoft, MD, PhD, Knud Nørregaard Hansen, MD, Evald Høj Christiansen, MD, PhD, Steen Dalby Kristensen, MD, DMSci, Jan Ravkilde, MD, DMSci, Morten Madsen, MSc, Henrik Toft Sørensen, MD, DMSci, PhD, Leif Thuesen, MD, DMSci, Jens Flensted Lassen, MD, PhD 
American Journal of Cardiology 
Volume 110, Issue 11, Pages (December 2012)
DOI: /j.amjcard
Copyright © 2012 Elsevier Inc. Terms and Conditions

2. Figure 1
Time-to-event curves for major adverse cardiac events (composite of cardiac death, myocardial infarction, definite stent thrombosis, and target vessel revascularization) in patients (A) with and without diabetes, (B) with diabetes after implantation of everolimus-eluting or sirolimus-eluting stents, and (C) without diabetes after implantation of everolimus-eluting or sirolimus-eluting stents.
American Journal of Cardiology  , DOI: ( /j.amjcard )
Copyright © 2012 Elsevier Inc. Terms and Conditions

3. Figure 2
Time-to-event curves for target lesion revascularization in patients (A) with and without diabetes, (B) with diabetes after implantation of everolimus-eluting or sirolimus-eluting stents, and (C) without diabetes after implantation of everolimus-eluting or sirolimus-eluting stents.
American Journal of Cardiology  , DOI: ( /j.amjcard )
Copyright © 2012 Elsevier Inc. Terms and Conditions